NCT04783545View on ClinicalTrials.gov

Phase I Study of VLX-1005 in Healthy Subjects

PHASE1CompletedINTERVENTIONAL
Enrollment

96

Participants

Timeline

Start Date

March 24, 2021

Primary Completion Date

January 11, 2022

Study Completion Date

January 11, 2022

Conditions
Safety and Tolerability in Healthy Volunteers
Interventions
DRUG

VLX-1005

VLX-1005 infusion

DRUG

Placebo

Placebo infusion

Trial Locations (1)

68502

Celerion, Inc., Lincoln

Sponsors
All Listed Sponsors
lead

Veralox Therapeutics

INDUSTRY

NCT04783545 - Phase I Study of VLX-1005 in Healthy Subjects | Biotech Hunter | Biotech Hunter